David Balto, who previously served as policy director at the Federal Trade Commission (FTC) and who now represents opponents of the proposed Express Scripts and Medco merger, made a compelling case in a leading Capitol Hill newspaper against the emergence of a mega-pharmacy-benefit-manager (PBM).